Clinical remission and associated factors in severe eosinophilic asthma patients treated with benralizumab: a real-world study
- 1Division of Immunology and Allergy Diseases, Department of Chest Diseases, University of Health Sciences, Ankara Atatürk Sanatorium Training and Research Hospital
Abstract
Background This study aimed to evaluate changes in clinical, functional, and inflammatory parameters in patients with severe eosinophilic asthma receiving benralizumab treatment, to determine clinical remission rates, and to explore factors associated with clinical remission. Methods This retrospective single-center real-world study included 33 patients with severe eosinophilic asthma treated with benralizumab at a tertiary referral center. Demographic characteristics, clinical findings, pulmonary function test results, peripheral blood eosinophil counts, and treatment responses were obtained from medical records. Baseline findings were compared with those obtained after at least 12 months of treatment. Clinical remission was defined as the absence of exacerbations, no maintenance oral corticosteroid use, well-controlled asthma, and stable or improved lung function. Factors associated with clinical remission were evaluated using multivariable Firth’s penalized logistic regression. Results The mean age of the 33 included patients was 54.6 ± 13.8 years, and 60.6% were female. After 12 months of treatment, clinical remission was achieved in 75.8% (25/33) of patients. The proportion of patients with well-controlled asthma increased to 90.9%, while maintenance oral corticosteroid use decreased from 48.5% to 24.2% (p = 0.008). The median annual exacerbation rate decreased from 2 to 0 (p < 0.001). Mean FEV₁ increased from 1514 mL to 2188 mL (+ 674 mL; p < 0.001), and FEV₁ (% predicted) improved from 54.9% to 76.8% (p < 0.001). Peripheral blood eosinophil counts decreased from a median of 720 cells/µL to 0 cells/µL (p < 0.001). In multivariable analysis, lower baseline exacerbation frequency (OR 0.52, 95% CI 0.27–0.91; p = 0.021) and higher baseline FEV₁ (per 100 mL increase; OR 1.27, 95% CI 1.01–1.59; p = 0.037) were associated with clinical remission. Conclusions Benralizumab was associated with high clinical remission rates, substantial reductions in exacerbations, and significant improvements in lung function in patients with severe eosinophilic asthma. Given the limited sample size, the findings from the exploratory multivariable analysis should be interpreted with caution and require confirmation in larger prospective studies.
Related
- Beyond eosinophil depletion: long-term clinical trajectory and durability of response to benralizumab in patients with severe eosinophilic asthma and CRSwNP: an 18-month real-world study (the BANDOR study)
- Achieving clinical and histologic remission with tezepelumab in an adolescent with refractory eosinophilic gastrointestinal disease: A case report
- Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A One-Year Single-Center Retrospective Study
- Beyond Eosinophil Depletion: Toward Multidimensional Remission in Eosinophilic Gastritis and Duodenitis.
- Clinical and MRI features associated with remission following biological therapy in axial spondyloarthritis
BibTeX
@article{yagdıran2026clinical,
title = {{Clinical remission and associated factors in severe eosinophilic asthma patients treated with benralizumab: a real-world study}},
author = {Melis Yağdıran and Kurtuluş Aksu},
journal = {BMC Pulmonary Medicine},
year = {2026},
month = jul,
doi = {10.1186/s12890-026-04518-2},
url = {https://doi.org/10.1186/s12890-026-04518-2},
note = {CC BY},
}
RIS
TY - JOUR
TI - Clinical remission and associated factors in severe eosinophilic asthma patients treated with benralizumab: a real-world study
AU - Melis Yağdıran
AU - Kurtuluş Aksu
PY - 2026
DA - 2026/07/01
JO - BMC Pulmonary Medicine
DO - 10.1186/s12890-026-04518-2
UR - https://doi.org/10.1186/s12890-026-04518-2
AB - Background This study aimed to evaluate changes in clinical, functional, and inflammatory parameters in patients with severe eosinophilic asthma receiving benralizumab treatment, to determine clinical remission rates, and to explore factors associated with clinical remission. Methods This retrospective single-center real-world study included 33 patients with severe eosinophilic asthma treated with benralizumab at a tertiary referral center. Demographic characteristics, clinical findings, pulmonary function test results, peripheral blood eosinophil counts, and treatment responses were obtained from medical records. Baseline findings were compared with those obtained after at least 12 months of treatment. Clinical remission was defined as the absence of exacerbations, no maintenance oral corticosteroid use, well-controlled asthma, and stable or improved lung function. Factors associated with clinical remission were evaluated using multivariable Firth’s penalized logistic regression. Results The mean age of the 33 included patients was 54.6 ± 13.8 years, and 60.6% were female. After 12 months of treatment, clinical remission was achieved in 75.8% (25/33) of patients. The proportion of patients with well-controlled asthma increased to 90.9%, while maintenance oral corticosteroid use decreased from 48.5% to 24.2% (p = 0.008). The median annual exacerbation rate decreased from 2 to 0 (p < 0.001). Mean FEV₁ increased from 1514 mL to 2188 mL (+ 674 mL; p < 0.001), and FEV₁ (% predicted) improved from 54.9% to 76.8% (p < 0.001). Peripheral blood eosinophil counts decreased from a median of 720 cells/µL to 0 cells/µL (p < 0.001). In multivariable analysis, lower baseline exacerbation frequency (OR 0.52, 95% CI 0.27–0.91; p = 0.021) and higher baseline FEV₁ (per 100 mL increase; OR 1.27, 95% CI 1.01–1.59; p = 0.037) were associated with clinical remission. Conclusions Benralizumab was associated with high clinical remission rates, substantial reductions in exacerbations, and significant improvements in lung function in patients with severe eosinophilic asthma. Given the limited sample size, the findings from the exploratory multivariable analysis should be interpreted with caution and require confirmation in larger prospective studies.
SN - 1471-2466
ER -